Tweet Send to a Friend PRINCETON, N.J., May 8, 2013 /PRNewswire/ -- Novo Nordisk announced that a new survey of women on local estrogen therapy revealing key insights into reasons for treatment non-compliance was published in the International Journal of Women's Health. The study, "Improved Compliance and Patient Satisfaction with Estradiol Vaginal Tablets in Postmenopausal Women Previously Treated with Another Local Estrogen Therapy," offers insight into reasons that various treatment regimens for vaginal atrophy (VA) may prove unsuccessful. (Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO ) VA is a treatable chronic condition that affects the vagina and the surrounding tissues...
↧